March 9, 2022
Johnson & Johnson Vision Care, Inc.,1, 2 announced that the U.S. Food and Drug Administration (FDA) has approved ACUVUE Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen). Each lens contains 19 mcg ketotifen. Ketotifen is a well-established antihistamine. ACUVUE Theravision with Ketotifen is the first in an entirely new category of contact lenses and brings forward a new wearing experience for contact lens wearers with allergic eye itch.
ACUVUE Theravision with Ketotifen are daily disposable contact lenses indicated for the prevention of ocular itch due to allergic conjunctivitis and provide vision correction in patients who do not have red eyes, who are suitable for contact lens wear and who do not have more than 1.00 D of astigmatism.
Within the U.S., approximately 40 percent of contact lens wearers suffer from itchy eyes due to ocular allergies,3 and nearly 8 out of 10 contact lenses wearers with eye allergies agree that they are frustrated when allergies interfere with their normal contact lens wear.4 While allergy eye drops are a common treatment, one-in-two contact lens wearers say that the drops are inconvenient to use.5
This announcement follows positive Phase 3 clinical studies published in the journal Cornea and regulatory approval by the Japanese Ministry of Health, Labor and Welfare, and Health Canada, where patients already have access to the new lenses.i According to the Phase 3 clinical studies, ACUVUE Theravision with Ketotifen showed a clinically and statistically meaningful reduction in itchy allergy eyes as quickly as three minutes after lens insertion and lasting up to 12 hours; however, the lens may be worn for longer than 12 hours for vision correction.
“Ocular allergic itch in contact lens wearers may soon be an issue of the past thanks to the decision of the FDA in approving ACUVUE Theravisionwith Ketotifen,” said Brian Pall, OD, MS, FAAO, Director, Clinical Science, Johnson & Johnson Vision Care.6 “These new lenses may help keep more people in contact lenses, since they relieve allergic eye itch for up to 12 hours, without the need for allergy drops, and provide vision correction.”
Other Articles to Explore
“At Johnson & Johnson Vision, we are committed to bringing forward new technologies and innovations that can improve vision and overall eye health,” said Thomas Swinnen, President, North America, Johnson & Johnson Vision Care, Inc.7 “This approval marks another significant milestone in Johnson & Johnson Vision’s legacy of rethinking what’s possible with contact lenses to meet the visual and eye health needs of people around the world.”
1. Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
2.The Johnson & Johnson Medical Device Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment.
3. JJV Data on File 2019. Online consumer allergy landscape survey of patients self-identifying as eye allergy sufferers within the USA (n=1212)
4. JJV Data on File 2019. Online consumer allergy landscape survey of patients self-identifying as eye allergy sufferers within the USA (n=521)
5. JJV Data on File 2019. Online consumer allergy landscape survey of patients self-identifying as eye allergy sufferers within the USA (n=293)
6. Brian Pall, OD, MS, FAAO, is an employee of Johnson & Johnson Vision Care, Inc. with oversight as Director of Clinical Science of the Vision Care organization.
7. Thomas Swinnen is an employee of Johnson & Johnson Vision Care, Inc.
i. Pall, B., Gomes, P., Yi, F., & Torkildsen, G. (2019). Management of Ocular Allergy Itch With an Antihistamine-Releasing Contact Lens. Cornea, 38(6), 713–717. https://doi.org/10.1097/ICO.0000000000001911